Syncor sees jump in operating income
Radiopharmaceutical firm Syncor International had reason to celebrate this month when it posted a dramatic increase in operating income for third quarter 1999 (end-September). The Woodland Hills, CA, firm’s operating income climbed 48% during the
Radiopharmaceutical firm Syncor International had reason to celebrate this month when it posted a dramatic increase in operating income for third quarter 1999 (end-September). The Woodland Hills, CA, firms operating income climbed 48% during the quarter, to $8.3 million from $5.6 million the year before. Net sales increased by 15% to $131.5 million, up from $114 million in 1998. The company reported net income of $3.2 million, compared with $2.7 million for the same period the previous year. Included in Syncors results was a nonoperating write-down of $1.8 million linked to the companys 1997 investment in Perimunne, a biotechnology company.
The company attributed its strong performance to increased market demand for pharmacy services, as well as sales revenue and acquisitions in its medical imaging business. For the quarter, Syncors radiopharmacy gross margin increased by $4.3 million to comprise 27% of the companys sales. Its medical imaging business, which operates under a subsidiary, Comprehensive Medical Imaging, posted sales of $15.7 million for the quarter, compared to $11 million in 1998. Comprehensive Medical Imaging acquired four imaging centers in Southern and Central California during the quarter.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
